Multiple Myeloma

A panel of experts on multiple myeloma offer insights on the case of a 57-year-old with relapsed/refractory MM treated with an FcRH5 bispecific antibody who develops peripheral neuropathy.

Registered Nurse Annel Urena presents the case of a 79-year-old female with IgG Kappa multiple myeloma and five previous lines of therapy.

A brief review of available management strategies used in practice when patients with multiple myeloma develop immune effector cell-associated neurotoxicity syndrome.

Jack Khouri, MD, presents the case of a 68-year-old patient with relapsed/refractory multiple myeloma and extramedullary disease treated with teclistamab.

Before closing out their program on bispecifics in multiple myeloma, expert oncologists consider the value of these agents in more challenging patient populations.

Centering discussion on transplant ineligible multiple myeloma, expert panelists review mainstay treatment regimens and strategies in the first-line setting.

Shared insight on the respective value of consolidation therapy and collaborative tumor boards when managing patients with transplant-eligible multiple myeloma.

C. Ola Landgren, MD, PhD, discusses the benefits obtained when patients have access to a full team of diverse caregivers rather than just a single physician.

C. Ola Landgren, MD, PhD, reviewed the plethora of emerging treatment options in multiple myeloma, and how unmet needs in the space can be overcome.

Ashley E. Rosko, MD, reviews unmet needs and treatment sequencing for patients with multiple myeloma.

Nurse Practitioner Kiah Purcell presents a case of a 74-year-old male with kappa light chain myeloma after ten lines of therapy.

Switching focus to the second patient case of multiple myeloma, panelists reflect on the prevalence and impact of ICANS on patients being treated with bispecific antibodies.

An expert panel discusses the management of dysgeusia associated with bispecific antibodies in treating patients with multiple myeloma.

Comprehensive insight on the grading system for cytokine release syndrome and available treatment strategies utilized in practice when patients with multiple myeloma develop CRS.

Annel Urena, RN, BSN, presents the case of a 69-year-old male with relapsed refractory IgG Lambda multiple myeloma after six lines of therapy.

Experts on multiple myeloma present the case of a 61-year-old with relapsed/refractory multiple myeloma (MM) treated with a BCMA bispecific antibody who develops dysgeusia and offer their initial impressions.

Following their review of non-BCMA-targeting bispecifics in multiple myeloma, panelists consider practical use of these agents and how they may fit into the real-world treatment paradigm.

A brief discussion on clinical trial data with cevostamab therapy followed by considerations for other non-BCMA-targeted agents being studied in the setting of multiple myeloma.

Among those with multiple myeloma, Hispanic patients may experience worse outcomes such as in-hospital mortality vs other ethnic groups.

A brief overview of stem cell transplant’s role in the first-line treatment setting of newly diagnosed multiple myeloma.

Expert panelists review available induction therapy regimens for patients newly diagnosed with transplant-eligible multiple myeloma in the context of clinical data.

C. Ola Landgren, MD, recaps a recent panel discussion of the rapidly changing treatment landscape in multiple myeloma, and prospects for future development.

Findings from the phase 1/2 MajesTEC-1 trial suggest that preemptively planning and promptly managing cytokine release syndrome with supportive care in patients with multiple myeloma treated with T-cell–engaging bispecific antibodies may be beneficial.

Robert Mancini, PharmD, and Kiah Purcell, AGPCNP-B, discuss other targets for bispecific antibodies in multiple myeloma treatment and the infection patterns.

A brief review of bispecific antibody dosing strategies in multiple myeloma to improve patient outcomes and address concurrent adverse events.